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Abstract.  Monoclonal antibodies binding to distinct 
epitopes on the tail  of brush border myosin were used 
to modulate the conformation and state of assembly of 
this myosin.  BM1  binds  1:3 of the distance from the 
tip of the tail  to the head and prevents the extended- 
tail (6S) monomer from folding into the assembly- 
incompetent folded-tail (10S) state,  whereas BM4 binds 
to the tip of the myosin tail,  and induces the myosin to 
fold into the  10S state.  Thus,  at physiological ionic 
strength BM1  promotes and BM4 blocks the assembly 
of the myosin into filaments.  Using BM1  and BM4 to- 
gether,  we were able to prevent both folding and fila- 
ment assembly, thus locking myosin molecules in the 
extended-tail 6S monomer conformation at low ionic 
strength  where they normally assemble into filaments. 
Using these myosin-antibody complexes, we were 
able to investigate independently the effects of folding 
of the myosin tail  and assembly into filaments on the 
myosin MgATPase. The enzymatic activities were 
measured from the fluorescent profiles during the turn- 
over of the ATP analogue formycin triphosphate 
(FTP).  Extended-tail  (6S) myosin molecules had an 
FTPase activity of 1-5  x  10  -3 s  -j, either at high ionic 
strength as a monomer alone or when complexed with 
antibody, or at low ionic strength as filaments or when 
maintained as extended-tail monomers by the binding 
of BM1  and BM4.  Folding of the molecules into the 
10S state reduced this rate by an order of magnitude, 
effectively trapping  the products of FTP hydrolysis in 
the active sites. 
N 
'ONMUSCLE myosins can exist in vitro as monomers 
with folded tails or with extended  tails (sedimenta- 
tion coefficients 10S and 6S respectively), or as illa- 
ments (Scholey et al., 1980; Citi and Kendrick-Jones,  1986). 
The position of the equilibrium between these conformations 
is determined by a number of factors including ionic strength, 
the state of myosin light chain phosphorylation, and the pres- 
ence of MgATP (Kendrick-Jones  et al., 1982; Scholey et al., 
1983; Kendrick-Jones  et al., 1987). When the myosin adopts 
the folded conformation, the products of nucleotide hydroly- 
sis are trapped at the active sites (Cross et al., 1986, 1988). 
In contrast, when the molecules are extended, as for example 
in  t>300 mM NaCI, the rate of release of the products of 
nucleotide hydrolysis  is at least 200-fold  faster.  Since fila- 
mentous myosin released the products of hydrolysis at a rate 
comparable to that of extended monomer,  it was suggested 
that the folding of the myosin tail was involved in nucleotide 
trapping  (Cross et al.,  1988). To test this hypothesis and in- 
vestigate  the role of the myosin tail  in the conformational 
changes that the myosin molecule can undergo (e.g., in fold- 
ing,  unfolding,  and filament  assembly), we have used two 
anti-(brush  border myosin)  monoclonal antibodies.  These 
antibodies bind to epitopes in two regions of the molecule (a) 
at the tip of the tail (BM4) and (b) '~1:3 of the distance from 
the tip of the tail to the head (BM1). In previous studies, these 
and other antibodies have proved useful in probing the struc- 
ture and function of this myosin in vitro (Citi and Kendrick- 
Jones,  1987; Citi  and  Kendrick-Jones,  1988) and  in  vivo 
(Hoener et al.,  1988). 
At physiological  ionic strength,  the antibodies allowed us 
to block selectively either filament  formation  or folding or 
both and to correlate the induced changes in myosin confor- 
mation with the changes in the rates of release of the products 
of nucleotide hydrolysis  from the active sites in the myosin 
heads. The conformation and state of assembly of the myosin 
in  each myosin-antibody  complex was established  by EM 
and  sedimentation  experiments.  Measuring  the enzymatic 
activities of these antibody-myosin  complexes using  formy- 
cin  triphosphate  (Jackson  and  Bagshaw,  1988a)  demon- 
strated  that  the trapped  state  is  a  property exclusively  of 
folded molecules, and  that  assembly into  filaments  per se 
does not greatly affect the enzymatic activity of the extended 
myosin molecules. 
Materials and Methods 
Materials 
Formycin triphosphate was prepared as described previously (Jackson and 
Bagshaw, 1988a). Adenosine triphosphate was obtained from Calbiochem 
Behring Corp. (San Diego, CA). All other chemicals (enzyme grade) were 
obtained from British Drug Houses (Poole, Dorset,  U.K.). 
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Myosin was prepared from chicken intestinal  epithelial  cells and dephos- 
phorylated using purified chicken gizzard  myosin light chain phosphatase, 
as described previously  (Citi and Kendrick-Jones,  1986). 
Monoclonal anti-(brush border myosin) antibodies were purified  from 
hybridoma culture supematants as described in Citi and Kendrick-Jones 
(1987). The pure antibodies (at concentrations in the range of 25-100/zM), 
in  150 mM  NaCI,  25  mM  NaH2POdNa~HPO4,  1 mM  NaN3,  pH  7.3 
(PBS) were stored at 4°C (short term) or at -20°C (long term). The posi- 
tion of the binding site of each antibody on the myosin rod is shown schemat- 
ically  in Fig.  1 A. 
Biochemical Methods 
Sedimentation Experiments. To determine the effect of the monoclonal an- 
tibodies and Fab fragments on the solubility  of brush border myosin,  a 
modification  of the sedimentation assay  previously  described (Kendrick- 
Jones et al.,  1987) was used.  Aliquots of nonphosphorylated brush border 
myosin (in 0.6 M NaCI,  1 mM EGTA,  25 mM Tris-HC1, pH 7.5, 0.1 mM 
DTT)  were mixed in tubes (Eppendorf made by Brinkmann Instruments, 
Inc., Westbury, NY) with either a small volume of PBS (control  with no 
antibody), or purified  monoclonal antibodies or Fab fragments or control 
Ig (all in PBS), to obtain a final myosin concentration of 0.7 ~M and a final 
antibody concentration of 0.8-3/zM. The mixtures were adjusted to 0.6 M 
NaCI by the addition of 4 M NaCl if necessary.  To half of each mixture 5 
mM MgATP was added, and this half was dialyzed separately into 175 mM 
NaCl, 5 mM MgCl2,  2 mM ATP, 1 mM EGTA, 20 mM imidazole,  pH 
7.2, and 0.1 mM DTT (buffer F). The other halves of each mixture were 
dialyzed  into 175 mM NaCI,  5 mM MgCl2,  1 mM EGTA,  20 mM imida- 
zole, pH 7.2, 0.1 mM DTT (buffer F without ATP). After 90-min dialysis, 
an aliquot of each sample was taken ("total" myosin), and the remaining di- 
alysate was centrifuged  at 28 psi (100,000 g) for 20 min in the airfuge.  The 
top two-thirds of each supernatant after centrifugation were carefully pipet- 
ted out, and used for the determination of the "soluble" myosin.  Because 
of the presence of the antibodies, the concentration of the myosin could not 
be measured directly. Thus, identical  volumes  of the samples  before cen- 
trifugation (total) and of the supernatants  after centrifugation were diluted 
with equal volumes of SDS sample buffer, and 5-10/zl of each sample were 
run on 5-20% polyacrylamide  gradient SDS gels.  The amount of myosin 
present in each sample was determined by densitometry of the myosin heavy 
chain bands. The concentration of"soluble" myosin (nonfilamentous myosin 
remaining in the supernatant after centrifugation at 100,000 g) was then ex- 
pressed as a percent of the total myosin concentration (Fig.  1 B). To deter- 
mine the amounts of soluble myosin present in the FTPase assays,  these 
sedimentation experiments were  repeated  under the same conditions as 
those used for these assays. The myosin (0.5 #M) and either intact antibody 
(1.5 #M) or Fab derivative (1 #M) were mixed together at 0.3 M NaCI and 
incubated in ice for 30 min. They were then diluted to a final concentration 
of 75 mM NaCI,  2 mM MgCl2,  1 mM EGTA,  10 mM imidazole  pH 7.0, 
0.5 mM DTT in the presence or absence of I mM MgATP and thoroughly 
mixed.  Aliquots were taken for "total" myosin samples and the remainder 
centrifuged in the airfuge at 28 psi for 20 min and processed  as described 
above (Fig.  1 C). 
Formycin  Triphosphatase  (FTP)  j Assays.  Assays using formycin  tri- 
phosphate were carried out as described by Jackson and Bagshaw (1988a). 
The myosin-antibody  complexes  were  prepared by  mixing nonphospho- 
rylated brush border myosin (in 0.6 M NaCI,  1 mM EGTA,  25 mM Tris- 
HCI pH 7.5, 0.1 mM DTT) with the purified monoclonal antibodies at 0.3 M 
NaCI to give a myosin concentration of 0.5 ~tM and a concentration of each 
antibody of 1-2 ttM. The myosin-antibody  complexes  and myosin control 
(without antibody) were incubated at 20°C for 10 min and then in ice for 
30 min. They were diluted to a final concentration of 75 mM NaCl, 1 mM 
EGTA,  2 mM MgCl2,  10 mM imidazole  pH 7.0, 0.5 mM DTT, and as- 
sayed. Fluorescence measurements were made using a ratio recording spec- 
trofluorimeter with a 5-mm path-length cell as described by Jackson and 
Bagshaw (1988b). Formycin fluorescence  was excited at X 313 nm and the 
emission monitored at X 350 nm. Data were digitized as 500 x  12 bit points 
using a microcomputer (II+; Apple Computer Inc., NY, NY), and were 
subsequently  transferred to  a  computer  for  least  squares  (300  series; 
Hewlett-Packard  Co., Palo Alto, CA) fitting to a single or double exponen- 
tial function using the Marquadt algorithm. 
Protein Concentrations and Gel Electrophoresis.  Protein  concentra- 
tions during the preparation of myosin and antibodies were measured by the 
method of Lowry et al. (1951), using BSA as a standard.  The concentration 
1. Abbreviation used in this paper:  FTE formycin triphosphate. 
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Figure 1. The effects of the monocional antibodies on the solubility 
of brush border myosin. (A) Diagram showing a cartoon of the myo- 
sin molecule,  with the positions of the binding sites of the two 
monoclonal antibodies used in this study.  (B) Histogram showing 
the amounts of nonassembled myosin (determined using the sedi- 
mentation assay) in the presence of monoclonal antibodies BMI and 
BM4  and  their respective Fab  fragments,  in the  absence  (white 
bars)  and  in the presence (shaded  bars)  of MgATP  at  175  mM 
NaC1. The error bars are standard deviations based on three deter- 
minations.  Myosin alone and  myosin-antibody mixtures (myosin 
concentration 0.7/~M, antibody concentration 0.8-3 ~M) were dia- 
lysed into buffer F  (175 mM NaCI,  5  mM MgCI2,  1 mM  EGTA, 
20 mM imidazole, pH 7.2, 0.1 mM DTT,  +2 mM MgATP at 4°C). 
An aliquot of each was taken and the remaining dialysate was cen- 
trifuged at 100,000 g, to sediment filaments. The percent of myosin 
in the supernatant was calculated by comparing the densitometer 
scans of the myosin heavy chain band (at 200 kD) in the sample 
before centrifugation (which was taken as 100%) and after centrifu- 
gation,  none,  no  antibody;  control,  control  immunoglobin.  (C) 
Histogram showing the amounts of nonassembled myosin (deter- 
mined using the sedimentation assay described above) in the pres- 
ence of monoclonal antibodies BMI and BM4 and their respective 
Fab  fragments,  in the  absence  (white bars)  and  in the  presence 
(shaded bars) of MgATP at 75 mM NaCI;  i.e.,  under conditions 
as close as possible to those used in the FTPase assays. The myosin 
(0.5 #M) and either the intact antibodies (1.5/~M) or their Fab de- 
rivatives (1/~M) were mixed together at 0.3 M  NaCI and incubated 
on ice for 30 min. They were then diluted to a final concentration 
of 75 mM NaC1,  2  mM MgCI2,  1 mM EGTA,  10 mM imidazole 
pH 7.0, 0.5 mM DTT in the presence and absence of I mM MgATP, 
thoroughly mixed and processed by the "sedimentation assay" de- 
scribed above, none, no antibody and MgATP added to preformed 
filaments at 75  mM  NaCI;  *control,  control  immunoglobin and 
MgATP added to the myosin at high salt before dilution to 75 mM 
NaC1. 
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coefficient (A2s0 .r,) of 0.54 mg  -I ml  -l cm  -t. 
PAGE in the presence of SDS was carried out as described by Matsudaira 
and Burgess (1978),  using 5-20% polyacrylamide gradient gels calibrated 
with myosin heavy chain (relative molecular mass of 200 kD), phosphory- 
lase B (95 kD), albumin (68 kD), skeletal muscle actin (42 kD), and skeletal 
muscle myosin light chain (25 kD). For densitometry, the gels were stained 
in a 0.1% wt/vol solution of Coomassie brilliant blue (PAGE Blue 83, BDH) 
in 50% methanol, 10% acetic acid, destained in 10% methanol, 10% acetic 
acid, and dried. The gels were scanned using a laser scanning densitometer. 
Images of the gel were stored and analyzed using an interactive computer 
program written for the Vax  8600  by Judy Smith (manuscript in prepa- 
ration). 
Electron Microscopy.  Folded brush border myosin molecules were pre- 
pared by dialyzing a solution of nonphosphorylated myosin (1 #M in 0.6 M 
NaCl, 25 mM Tris-HCI, pH 7.5, 0.5 mM EGTA, 0.1 mM DTT) against 175 
mM NaCI, 5 mM MgATP,  20 mM imidazole, pH 7.2, 0.1 mM DTT,  0.5 
mM EGTA, for 90 min. Previous studies (Kendrick-Jones et al., 1987) have 
established that the half-time for NaCI equilibration during dialysis is of the 
order of 10 rain. The dialysate was centrifuged for 20 min at  17 psi in an 
airfuge (Beckman Instruments, Inc., Palo Alto, CA), the supernatant was 
taken, and the myosin concentration determined by the method of Lowry 
et al. (1951). To prepare myosin-antibody complexes, aliquots of the super- 
natant (containing folded myosin molecules) were mixed with a small vol- 
ume of purified monoclonal antibody (25-100  #M  in PBS,  with 5  mM 
MgATP added), and each mixture was further diluted, if necessary, with 
dialysis buffer to obtain a final myosin concentration in the range of 0.4-0.6 
#M  and an antibody concentration of 1-2.5  /~M.  The samples were in- 
cubated for 4 h on ice, diluted with an equal volume of glycerol (final myosin 
concentration 0.2-0.3  #M),  mixed thoroughly and  sprayed onto freshly 
cleaved mica for rotary shadowing (Citi and Kendrick-Jones, 1987).  The 
grids were examined in an electron microscope (Philips Electronic Instru- 
ments, Inc., Mahwah, N J), operated at 80 kV. 
Aliquots of the myosin and myosin-antibody complexes were taken from 
the FTPase assays and negatively stained as described previously (Citi and 
Kendrick-Jones, 1986) and examined in the electron microscope. 
Results 
Perturbation of the Monomer-Polymer Equilibrium of 
Brush Border Myosin by Monoclonal Antibodies 
The effects of the antibodies on the solubility of the myosin 
in vitro at approximately physiological ionic strength was de- 
termined using a sedimentation assay (Fig.  1 B). With '~1 
/~M nonphosphorylated brush border myosin in the absence 
of MgATP, '~90% of the myosin was filamentous and thus 
pelleted,  whereas  in  MgATP  only  ~25%  of the  myosin 
pelleted, and ,'~75% was in the supernatant (Fig. 1 B). This 
was in agreement with our previous observations, showing 
that at physiological ionic strength,  MgATP disassembles 
brush  border  myosin filaments (Citi and Kendrick-Jones, 
1986; Kendrick-Jones et al.,  1987).  All the antibodies had 
a specific effect on the assembly of nonphosphorylated brush 
border myosin filaments, confirming our earlier results using 
electron microscopy (Citi and Kendrick-Jones,  1988).  For 
example, the binding of BM4 or BM4-Fab to the tip of the 
myosin tail resulted in a large increase in myosin solubility 
in the absence of MgATP (90-100 % of the myosin was solu- 
ble instead of ~10%), and also a less marked, but significant 
increase  in  myosin solubility in  the  presence  of MgATP 
(from '~75  % without the antibody to ~95 % in its presence). 
BM4 does in fact completely inhibit filament assembly (Citi 
and Kendrick-Jones, 1988). In the absence of MgATP the an- 
tibody BM1 and its Fab fragment had little effect on the solu- 
bility of the myosin, and the amount of soluble myosin with 
this antibody was very low, and similar to that obtained with 
the control (Fig. 1 B). This is in agreement with the observa- 
tion that BM1 allows filament assembly to occur (Citi and 
Kendrick-Jones,  1988).  When MgATP was present,  BM1 
dramatically  reduced  the  amount  of  soluble  myosin,  to 
values similar to those obtained in the absence of MgATP; 
thus ~90% of the myosin was pelleted (Fig. 1 B). A signifi- 
cant reduction in the amount of soluble myosin was also ob- 
served with BM1-Fab (only 20-30% of myosin remained in 
the supernatant). Although when examined in the electron 
microscope BM1 plus BM4 or their Fab derivatives com- 
pletely blocked filament assembly in the presence and ab- 
sence of MgATP (Table I), in the sedimentation assays ,,o40  % 
of the myosin pelleted in the presence of both intact antibod- 
ies (Fig. 1 B and C). This discrepancy is because of the for- 
mation of cross-linked nonfilamentous oligomers that occur 
in the presence of intact antibodies (see Table I). 
Do the Antibodies Inhibit the Folding of the Tail of 
Brush Border Myosin? 
Electron microscopic analysis of the myosin supernatants at 
approximately physiological ionic strength and in the pres- 
ence of MgATP showed that ~90%  of the soluble myosin 
('~70% of the total) was in a folded conformation (Table I). 
The folding of the tail into three segments generated mole- 
cules with a very compact structure in the electron micro- 
scope (Fig. 3 A) (see also Citi and Kendrick-Jones, 1986). 
When BM1 was added to the folded myosin, no folded mole- 
cules were seen, and ,~90% of the myosin was assembled 
into a homogeneous population of short (0.3-0.4/zm) bipolar 
filaments (Table I, Fig. 2 D).  Very occasionally oligomers 
(one example is shown in Fig. 2 D, c) or unpolymerized ex- 
tended  myosin molecules  complexed  with  the  antibodies 
were seen (Table I). Similar results were obtained when the 
myosin and antibody were mixed together before dialysis into 
buffer F (not shown), indicating that the effect of  the antibody 
is independent on whether it is added to the myosin before 
or after fokling. The observation that BM1-Fab had the same 
effect as BM1 (for example, see Fig. 2 D, d), was in agree- 
ment with the sedimentation assay, and was further proof  that 
Table L Quantitative  Analysis of  the Effects of  the 
Antibodies on the Folded  Myosin Conformation 
Folded  Extended 
Filamentous  tail  tail  Oligomers 
Low salt/ATP 
Control  25  70  2  3 
+BMI  92  0  6  2 
+BM4  0  59  4  37 
+BMI  +  BM4  0  1  29  70 
High salt 
Control  0  0  98  2 
The  percent of myosin molecules present  as  filaments  (filamentous)  or as 
monomers with extended tails or folded tails are shown. The values were ob- 
tained after examining 200-400 rotary shadowed molecules in electron micro- 
graphs at  30,000x.  The  samples for rotary  shadowing were prepared as 
described in Materials and Methods. High salt indicates molecules in 600 mM 
NaCI, 25 mM Tris-HCl, 5 mM Mg  ++, 0.1  mM DTT. Low salt/ATP indicates 
buffer F (175 mM NaCl, 5 mM MgCI2, 2 mM ATP,  1 mM EGTA, 20 mM 
imidazole, pH 7.2, 0. ! mM DTT). Oligomers includes small aggregates of my- 
osin molecules  (present in 600 mM NaCI or in buffer F) or molecules cross- 
linked by antibodies.  In the oligomers with BM4, the myosin molecules were 
mostly folded (see Fig. 2 B), whereas with BM1  +  BM4 they had extended 
tails (see Fig. 2 C). For BMI, the percent of filamentous myosin Was in agree- 
ment with the values obtained  with the sedimentation  assay (Fig.  l). 
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tron  micrographs  showing  the 
effects ofBM4, BM4 + BM1, and 
BMI on the conformation of  brush 
border  myosin  molecules.  (A) 
Folded brush border myosin mol- 
ecules, in the absence of antibody. 
(B)  Complexes  of myosin  with 
BM4. In m, an example of  two ex- 
tended  myosin molecules cross- 
linked by BM4 (arrow) is shown. 
(C)  Complexes  of myosin  with 
BMI  and BM4.  Arrows and ar- 
rowheads  in o,  s,  and t  indicate 
BM4 and BMI, respectively. The 
myosin molecules shown in o and 
s are monomers with an extended 
tail, present at physiological ionic 
strength.  (D) Complexes  of myo- 
sin  with  BMI  (a-c  and  e-g), 
and BMI-Fab (d). Central  "bare" 
regions  of the  filaments  (arrow- 
heads).  Note  the  homogeneous 
size distribution  of the filaments. 
Folded brush border myosin mol- 
ecules were prepared by dialyzing 
nonphosphorylated myosin (1 #M) 
into a solution containing 175 mM 
NaCI and 5 mM MgATP (buffer 
F) and centrifugation  at 100,000 g 
(see Materials and Methods).  The 
folded  myosin  was  mixed  with 
,,,1-2.5/~M purified  monoelonal 
antibody (or Fab), incubated  for 
4 h on ice, diluted 1:1 with glycer- 
ol, and the mixtures were sprayed 
immediately  onto mica for rotary 
shadowing. 
filament assembly was not because of nonspecific cross-link- 
ing of the myosin molecules into aggregates by the bivalent 
antibody.  Thus,  when BM1  binds to the folded molecules, 
the myosin unfolds and the extended molecules can assemble 
into short filaments. When examined in electron micrographs 
after rotary shadowing,  these  filaments displayed a  central 
zone,  apparently  devoid of antibodies  and  myosin  heads, 
'~35-nm long and ~24-nm wide (Fig.  2 D).  The two ends 
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more  irregular  in  shape,  and  contained  extended  myosin 
molecules, with their heads oriented away from the central 
bare zone (Fig. 2 D, arrowheads). When negatively stained 
and examined in the electron microscope, bipolar filaments 
with a homogeneous size distribution were observed. 
When BM4  was added to the folded molecules,  no illa- 
ments were observed, and >90 % of the soluble myosin mol- 
ecules remained in a compact folded conformation, with the 
antibody bound at the tip of the tail (Fig. 2 B). About a third 
of the folded molecules were complexed into oligomers by 
the divalent antibody;  i.e.,  into antiparallel  folded myosin 
dimers with molecules of antibody bound roughly in a cen- 
tral position (Table I) (Fig.  2 B, n). 
Finally, we examined electron micrographs of complexes 
of myosin molecules with BM1 and BM4 together (Fig. 2 C). 
The feasibility of such an approach was supported by solid 
phase competition assays, showing that neither antibody in- 
hibited the binding of the other to the same myosin molecule 
(not shown). Using these two antibodies, one of which (BM1) 
inhibits folding, while the other (BM4) inhibits assembly, es- 
sentially  no  folded  molecules or filaments were observed 
(Table I). The myosin was present as nonsedimentable spe- 
cies, with extended tails,  either as monomers with the two 
antibodies binding to their respective epitopes (Fig.  2  C, o 
and s), or as small oligomers cross-linked by one or both an- 
tibodies (Fig.  2  C, u and v). 
The Antibodies Produce Parallel Changes in Myosin 
Conformation and Enzymatic Activity 
The rate limiting step of myosin ATPase activity is,  under 
most conditions  that have been  studied,  a  conformational 
change that controls the release of the products, ADP and Pi. 
FTP,  a  fluorescent  ATP  analogue,  provides  a  convenient 
probe to follow the product release steps (Jackson and Bag- 
shaw,  1988a;  Cross et al.,  1988).  In a typical experiment, 
FTP was first mixed in a slight excess over the myosin active 
site concentration. When the binding phase was complete, as 
indicated by the maximum enhancement of fluorescence, the 
reaction was chased with a >100-fold molar excess of ATP. 
The subsequent decrease in fluorescence provides a direct 
measure of product release and may be described by one or 
more exponential  functions.  This approach is particularly 
powerful as it reveals populations or conformations of myo- 
sin, such as the 10S state, which have low turnover rates and 
may go undetected in conventional steady-state assays. 
In the sedimentation and electron microscope studies de- 
scribed above, the nucleotide concentration used to promote 
the  10S  state  was  />1  mM  ATP and  resulted  in  extensive 
solubilization of filamentous myosin at low ionic strength. 
The  fluorescence  measurements  using  FTP,  however,  in- 
volved only a  low initial  nucleotide  concentration  (2/zM) 
that  was  insufficient  to  cause  extensive  solubilization  of 
preformed filaments. However, if the FTP was added to myo- 
sin in 0.6  M  NaCI (i.e.,  initially in the 6S state) and then 
quickly diluted to 75 mM NaCI, the mixture remained non- 
turbid and a greater proportion of the FTP became trapped 
in the 10S form, which released products slowly. Fig. 3 com- 
pares the turnover of FTP in 300 mM NaCI, where the pre- 
dominant state is monomeric 6S myosin, with turnover in 75 
mM NaCI, where a mixture of filamentous and 10S myosin 
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Figure 3.  FTP turnover by the different conformational  states of 
brush border myosin.  1 #M brush border myosin "heads" were 
mixed with 2 #M FTP, and,  when the peak of fluorescence was 
reached, the reaction was chased with I mM MgATP. Reaction con- 
ditions:  10 mM imidazole,  1 mM MgCI2, 0.5 mM EGTA, 0.5 mM 
DDT at pH 7.0 and 20°C. (A) 300 mM NaCI, or (B and C) 75 mM 
NaCI. Formycin fluorescence was monitored using the same fluo- 
rimeter settings throughout and the baseline of the plot represents 
zero light intensity. (A) The myosin was predominantly  in the 6S 
form. A monophasic exponential fit to the fluorescence decay yield- 
ed a rate constant of 0.0051 s  -~. (B) The myosin was predominant- 
ly in the filamentous form and remained in this state when the FTP 
was added. A biphasic fit yielded rate constants of 0.0013 s  -t (80% 
amplitude)  and 0.008 s  -~ (20%  amplitude).  (C) The myosin and 
FTP were premixed in 300 mM NaC1, and then diluted to 75 mM 
NaCI after 20 s and transferred to the fluorimeter cell. A substantial 
fraction of the myosin became trapped in the  10S form as judged 
by the biphasic exponential fit to the data recorded over a 60-rain 
time base, which yielded rate constants of 0.00066 s  -~ (90% am- 
plitude) and 0.0062 s  -~ (10% amplitude). 
exists, in proportions dependent on the order of addition of 
FTP relative to the dilution step. The salt concentration was 
reduced to 75 mM to ensure that almost all the myosin was 
in filament form under the conditions used in Fig. 3 B. Anal- 
ysis of these profiles indicates that the turnover rate for 6S my- 
osin,  10S myosin and filamentous myosin are 5  x  10  -3 S -t , 
6  ×  10  -4 s  -~, and 1.3  ×  10  -3 S -I,  respectively. The value of 
the rate constant for the 6S state, however, contains an ele- 
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Figure 4. FTP turnover by brush border myosin in the presence of 
monoclonal antibodies. The fluorimeter settings and reaction con- 
ditions were the same as described in Fig. 3. All assays were per- 
formed in the final (NaCI) of 75 mM. The antibodies (1-2 #M) were 
preincubated with the brush border myosin (0.5 pM) for 10 min at 
20°C, and then a further 0.5 to 1.5 h at 0°C at a (NaCI) of '~ 300 
mM. FTP was added and then the mixture diluted after 20 s to 75 
mM NaCI, except in D where the myosin-antibody mixture was 
diluted  before  FTP addition.  (A) BMI antibody  that  resulted  in 
filamentous myosin. A biphasic exponential  fit yielded  rate con- 
slants of 0.0012 s  -t (78% amplitude)  and 0.0061 s  -~ (22% ampli- 
tude).  (B) BMI  +  BM4 antibody that held the myosin in the 6S 
conformation.  A biphasic  fit yielded  rate constants of 0.0017 s  -t 
(76% amplitude)  and 0.097 s  -t (24% amplitude).  (C) BM4 anti- 
body that held the myosin in the 10S conformation.  A biphasic fit 
yielded rate constants of 0.00046 s  -~ (92% amplitude) and 0.0031 
s  -~ (8% amplitude).  (D) As above but the myosin was diluted to 75 
mM NaCI before FTP addition. A biphasic exponential fit yielded 
rate constants of 0.00053 s  -~ (94% amplitude) and 0.0083 s  -~ (6% 
amplitude).  Records (C) and (D) were allowed to proceed for 60 
min to give an adequate fit to the slow phase. 
ment arising from the higher ionic strength. Using monoclo- 
nal antibodies to hold the myosin in a defined conformation 
potentially allows this problem to be overcome. 
FTP turnover by myosin preparations that had been prein- 
cubated with  monoclonal antibodies are shown  in  Fig.  4. 
BM1  alone prevents the formation of the  10S state, and,  in 
its presence, myosin shows a moderately high FTP turnover 
rate  (1.2  x  10  -3  s-')  (Fig.  4  A)  comparable  with  the 
filamentous form (Fig. 3 B). The enzymatic activity is fur- 
ther increased in the presence of both BM1  and BM4, and 
this condition permits a measurement of the turnover rate (1.6 
x  10  -3  S  -t)  of the  6S  conformation at  low  ionic  strength 
(Fig. 4 B). In contrast, BM4 alone prevents filament assem- 
bly and on dilution to low ionic strength formation of the 10S 
state is promoted. This is evident from the very slow FTP 
turnover rate (4.5  ×  10  -4 s -~) under these conditions (Fig. 
4 C). Furthermore the 10S state predominates regardless of 
the order of addition of FTP relative to dilution. Indeed when 
the BM4-myosin mixture was diluted to 75 mM NaCI before 
FTP addition (Fig. 4 D), the solution remained clear, indica- 
tive of the myosin being fixed in a monomeric state (cf., Fig. 
1 C). As soon as the FTP binds under these conditions, the 
myosin must rapidly fold into the 10S state and trap the prod- 
ucts. This contrasts with the corresponding experiment in the 
absence of BM4 (Fig.  3 B) where the filamentous myosin 
turns over the FTP relatively rapidly before the filaments can 
depolymerize, and only a small fraction of the myosin can 
trap the formycin nucleotide before the FTP is exhausted or 
is competed out with ATE 
To confirm these effects on the antibodies on myosin fila- 
ment assembly, aliquots of the FTPase assay solutions at the 
end of the experiments were analyzed in the electron micro- 
scope after negative staining. No filaments were observed in 
the myosin samples in the presence of BM4 or in the pres- 
ence ofBM1 +  BM4, whereas in the control and BMI prepa- 
rations,  filaments with  approximately uniform dimensions 
were clearly visible (Fig. 5). The control sedimentation ex- 
periments shown in Fig.  1 C confirm that at 75 mM NaCI, 
MgATP has very little effect on preformed filaments (only 
~15% of the myosin is soluble); whereas, when added to the 
myosin in high salt before dilution to 75 mM NaCI, at least 
65 %  of the  myosin then  remains  soluble.  Otherwise,  the 
effects of the antibodies on the "solubility" of the myosin at 
75 mM salt are qualitatively similar to those observed at about 
physiological ionic strength (175 mM NaCI) (compare Figs. 
1, B and C). 
Discussion 
Monoclonal Antibodies Modulate Myosin 
Monomer-Polymer Equilibria by Locking Myosin 
into One Conformational State 
We have described a novel approach to investigate the influ- 
ence of myosin conformation on its enzymatic activity, using 
specific monoclonal antibodies.  Antibodies BM4 and BM1 
alone lock the myosin into either a monomer or filamentous 
state,  and,  when used  in combination,  induce  the myosin 
molecule to be in an extended monomeric conformation, un- 
der conditions where normally it would be either in a folded 
conformation or in filaments. Such specific effects on myosin 
conformation have not been described  in previous studies 
using  monoclonal  antibodies  to  invertebrate myosins and 
vertebrate  smooth and  skeletal  muscle  myosins,  although 
effects on filament formation and the actin-activated myosin 
ATPase activity were observed (Kiehart et al., 1984; Kiehart 
and Pollard,  1984; Schneider et al., 1985; Winkelmann and 
Lowey,  1986;  Pagh and Gerisch,  1986; Citi and Kendrick- 
Jones,  1988). 
BM4  shifts the monomer-polymer equilibrium of brush 
border myosin towards the monomeric, unassembled state. 
As suggested previously (Citi and Kendrick-Jones,  1988), 
BM4, by binding to the tip of the myosin tail, inhibits the an- 
tiparallel interaction occurring in the initial step of filament 
assembly, and therefore blocks nucleation.  BM4,  however, 
does not inhibit the folding of brush border myosin or unfold 
previously folded molecules, showing that the tip of the rod 
can freely interact with the antibody without interfering with 
the folding process. 
BM1  allows nucleation  to occur but hinders  elongation; 
thus  the filaments formed are shorter (Citi  and  Kendrick- 
Jones,  1988)  (Fig.  5).  This antibody inhibits the transition 
between extended (6S) and folded (10S)  myosin molecules 
(at  physiological  ionic  strength  and  in  the  presence  of 
MgATP) (Fig.  1 and 2), and "locks" the myosin molecules 
in the extended state. These extended monomers can then as- 
The Journal of Cell Biology, Volume 109,  1989  554 Figure 5. Electron microscopic analysis of the effects of antibody binding on the assembly of brush border myosin in samples taken from 
the FTPase assays. (a) Brush border myosin filaments in the absence of antibody; (b) short myosin filaments in the presence of BMI; (c) 
the effects of BM4; and (d) BM1  +  BM4 on myosin filament assembly. Note the absence of recognisible filaments in c and d, instead 
an amorphous background of protein. For negative staining and electron microscopy, samples were taken directly from the assay solutions 
at the end of the experiments shown in Fig. 4 (conditions: 1 #M myosin heads and 1-2 #M antibodies in 75 mM NaCI, 10 mM imidazole, 
pH 7.0, 0.5 mM EGTA,  1 mM MgCI2, 0.5 mM DTT plus 2 #M FTP and 1 mM MgATP). 
semble into filaments via the antiparallel interactions of the 
myosin tails. There are a number of possible ways to explain 
how  this  antibody prevents  the  myosin tail  from folding. 
Firstly, if charge interactions between segments of  the tail are 
involved in stabilizing the folded conformation (Trybus and 
Lowey, 1984), it is possible that BM1 could inhibit such in- 
teractions, possibly by altering the charge distribution on the 
surface of the tail or by physically preventing the tail seg- 
ments from interacting. On the other hand, the folded con- 
formation could be stabilized by an interaction between the 
neck region of the myosin head and the tail, near its proximal 
hinge region (Craig et al.,  1983).  Since this region on the 
tail is close to the epitope where BM1 binds, BM1 may steri- 
cally inhibit such interaction. Thirdly, since BM1 binds near 
to one of the flexible sites in the myosin tail involved in fold- 
ing, it could modify the conformation of this region by lo- 
cally perturbing the structure of the c~ helical coiled coil. Fi- 
nally, we cannot exclude the possibility that the antibody may 
act via some yet unidentified long-range effect on the confor- 
mation of the whole molecule. 
Enzymology of the 6S Myosin Monomer-BM1-BM4 
Complex at Low Ionic Strength and Its Relevance 
In Vivo 
The extended tail monomer conformation (6S) of brush bor- 
der myosin is unstable at physiological ionic strength.  By 
stabilizing  this  energetically unfavorable conformation in 
vitro, BM1 and BM4 facilitate investigation of its enzymol- 
ogy.  This  6S-myosin monomer-antibody complex has  an 
FTPase activity very similar to that of the molecules assem- 
bled into filaments. Thus, when folding of the myosin tail is 
prevented by these antibodies, trapping of nucleotide does 
not occur. This indicates that the trapping of nucleotide at 
the active site is not because of a change in the structure of 
the myosin head,  occurring at low ionic strength,  but be- 
cause of  the folding of the myosin tail. Thus, filamentous my- 
osin and the 6S-myosin-BM1  +  BM4 complex at low ionic 
strength and the 6S-myosin at high ionic strength all have 
similar FTPase rates. In the 10S myosin-BM4 complex, the 
antibody maintains the folded state, and so the FTPase activ- 
ity is low. 
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of the 6S myosin-antibody complex (myosin-BM1  +  BM4) 
in the presence of actin in vitro. These studies require the 
use of monovalent antibody fragments, since in the presence 
of actin and the two bivalent antibodies the myosin shows an 
increased tendency to form oligomers  and aggregates (Citi 
and  Kendrick-Jones,  unpublished observations).  We  have 
previously shown that in phosphorylated myosin, there is a 
correlation  between  the  extent to  which these  antibodies 
block filament assembly and the degree to which they inhibit 
the  steady-state actin-activated  MgATPase  of the  myosin 
(Citi and Kendrick-Jones, 1988). BM4-Fab was found to be 
the  most  potent inhibitor  of  the  myosin  actin-activated 
MgATPase (Citi  and Kendrick-Jones,  1988),  because  not 
only does it prevent filament assembly, but it also appears to 
be the most effective at preventing aggregation which tends 
to occur in the presence of actin. 
BM1  and  BM4  have also  been  used  in  microinjection 
studies  to  probe myosin  function  in  vivo (Hoener  et  al., 
1988).  When these antibodies were separately injected into 
fibroblasts, they increased cell motility and membrane dy- 
namics,  and produced bizarre cell shapes,  suggesting that 
they interfere with myosin interaction with actin probably by 
reducing the amount of functional myosin in the cell (Hoener 
et al.,  1988).  Since we envisage that this is because of the 
ability of the antibodies to lock the myosin into filamentous 
(BM1) or monomer (BM4)  conformations, we suggest that 
the  dynamic  rearrangements and  transitions  between  the 
folded and filamentous states of the myosin are critical for 
its function within the cell. 
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